Pregnancy testing with hCG - future prospects

Trends in Endocrinology and Metabolism

Volumn 25, Issue 12, 2014, Pages 637-648

  Berger, Peter ^a   Sturgeon, Catharine ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Antibody standardisation; Fifth IS 07 364 for hCG; First IRR for hCG; HCG variants; Pregnancy testing

Indexed keywords

CHORIONIC GONADOTROPIN; EPITOPE; FOLLITROPIN; LUTEINIZING HORMONE; MONOCLONAL ANTIBODY; PROTEIN VARIANT; REAGENT;

AGGLUTINATION TEST; AMINO ACID ANALYSIS; ANTIBODY SPECIFICITY; BLOOD ANALYSIS; CHORIOCARCINOMA; DOWN SYNDROME; ECTOPIC PREGNANCY; EPITOPE MAPPING; FIRST TRIMESTER PREGNANCY; GERM CELL TUMOR; HORMONE DETERMINATION; HUMAN; IMMUNOASSAY; LABORATORY TEST; MASS SPECTROMETRY; MEASUREMENT ERROR; NONHUMAN; OVARY TUMOR; PREGNANCY; PREGNANCY TEST; PRENATAL SCREENING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SECOND TRIMESTER PREGNANCY; STANDARD; THREE DIMENSIONAL IMAGING; TRISOMY 21; TROPHOBLASTIC TUMOR; URINALYSIS;

EID: 84922817493     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.08.004     Document Type: Review

References (64)

1. Sturgeon C.M., McAllister E.J. Analysis of hCG: clinical applications and assay requirements. Ann. Clin. Biochem. 1998, 35(pt 4):460-491.
2. Stenman U.H., et al. Human chorionic gonadotropin in cancer. Clin. Biochem. 2004, 37:549-561.
3. Stenman U.H., et al. The classification, functions and clinical use of different isoforms of HCG. Hum. Reprod. Update 2006, 12:769-784.
4. de Medeiros S.F., Norman R.J. Human choriogonadotrophin protein core and sugar branches heterogeneity: basic and clinical insights. Hum. Reprod. Update 2009, 15:69-95.
5. Kicman A.T., et al. An introduction to mass spectrometry based proteomics-detection and characterization of gonadotropins and related molecules. Mol. Cell. Endocrinol. 2007, 260-262:212-227.
6. Berger P., et al. The ISOBM TD-7 Workshop on hCG and related molecules. Towards user-oriented standardization of pregnancy and tumor diagnosis: assignment of epitopes to the three-dimensional structure of diagnostically and commercially relevant monoclonal antibodies directed against human chorionic gonadotropin and derivatives. Tumor Biol. 2002, 23:1-38.
7. Birken S., et al. Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites. Clin. Chem. 2003, 49:144-154.
8. Bristow A., et al. Establishment, value assignment, and characterization of new WHO reference reagents for six molecular forms of human chorionic gonadotropin. Clin. Chem. 2005, 51:177-182.
9. Sturgeon C.M., et al. Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. Clin. Chem. 2009, 55:1484-1491.
10. Berger P., et al. Candidate epitopes for measurement of hCG and related molecules: the 2nd ISOBM TD-7 workshop. Tumor Biol. 2013, 34:4033-4057.
11. Fiddes J.C., Goodman H.M. Isolation, cloning and sequence analysis of the cDNA for the alpha-subunit of human chorionic gonadotropin. Nature 1979, 281:351-356.
12. Fiddes J.C., Goodman H.M. The cDNA for the beta-subunit of human chorionic gonadotropin suggests evolution of a gene by readthrough into the 3'-untranslated region. Nature 1980, 286:684-687.
13. Talmadge K., et al. The human genome contains seven genes for the beta-subunit of chorionic gonadotropin but only one gene for the beta-subunit of luteinizing hormone. DNA 1983, 2:281-289.
14. Policastro P.F., et al. A map of the hCG beta-LH beta gene cluster. J. Biol. Chem. 1986, 261:5907-5916.
15. Lapthorn A.J., et al. Crystal structure of human chorionic gonadotropin. Nature 1994, 369:455-461.
16. Toll H., et al. Glycosylation patterns of human chorionic gonadotropin revealed by liquid chromatography-mass spectrometry and bioinformatics. Electrophoresis 2006, 27:2734-2746.
17. Valmu L., et al. Site-specific glycan analysis of human chorionic gonadotropin beta-subunit from malignancies and pregnancy by liquid chromatography-electrospray mass spectrometry. Glycobiology 2006, 16:1207-1218.
18. McChesney R., et al. Intact HCG, free HCG beta subunit and HCG beta core fragment: longitudinal patterns in urine during early pregnancy. Hum. Reprod. 2005, 20:928-935.
19. Hay D.L. Discordant and variable production of human chorionic gonadotropin and its free alpha- and beta-subunits in early pregnancy. J. Clin. Endocrinol. Metab. 1985, 61:1195-1200.
20. Wide L., et al. A change in the isoforms of human chorionic gonadotropin occurs around the 13th week of gestation. J. Clin. Endocrinol. Metab. 1994, 78:1419-1423.
21. Birken S., et al. Metabolism of hCG and hLH to multiple urinary forms. Mol. Cell. Endocrinol. 1996, 125:121-131.
22. Kato Y., Braunstein G.D. Beta-core fragment is a major form of immunoreactive urinary chorionic gonadotropin in human pregnancy. J. Clin. Endocrinol. Metab. 1988, 66:1197-1201.
23. Kovalevskaya G., et al. Early pregnancy human chorionic gonadotropin (hCG) isoforms measured by an immunometric assay for choriocarcinoma-like hCG. J. Endocrinol. 1999, 161:99-106.
24. Burns C., et al. WHO International Collaborative Study of the proposed 5th International Standard for Chorionic Gonadotrophin 2009, http://whqlibdoc.who.int/hq/2009/WHO_BS_09.2107_eng.pdf.
25. Panteghini M. Traceability as a unique tool to improve standardization in laboratory medicine. Clin. Biochem. 2009, 42:236-240.
26. Sturgeon C.M., et al. Variation in parathyroid hormone immunoassay results - a critical governance issue in the management of chronic kidney disease. Nephrol. Dial. Transplant. 2011, 26:3440-3445.
27. Lund H., et al. Epitope analysis and detection of human chorionic gonadotropin (hCG) variants by monoclonal antibodies and mass spectrometry. Tumor Biol. 2014, 34:1013-1022.
28. Woldemariam G.A., Butch A.W. Immunoextraction-tandem mass spectrometry method for measuring intact human chorionic gonadotropin, free beta-subunit, and beta-subunit core fragment in urine. Clin. Chem. 2014, 60:1089-1097.
29. Kofler R., et al. Monoclonal antibodies against human chorionic gonadotropin (hCG): I. production, specificity, and intramolecular binding sites. Am. J. Reprod. Immunol. 1982, 2:212-216.
30. Berger P., et al. Antigenic features of human follicle stimulating hormone delineated by monoclonal antibodies and construction of an immunoradiomometric assay. Endocrinology 1988, 123:2351-2359.
31. Bidart J.M., et al. Immunochemical mapping of hCG and hCG-related molecules. Scand. J. Clin. Lab. Invest. Suppl. 1993, 216:118-136.
32. Berger P., et al. Immunochemical mapping of gonadotropins. Mol. Cell. Endocrinol. 1996, 125:33-43.
33. Berger P., Sturgeon C. Human chorionic gonadotropin isoforms and their epitopes: diagnostic utility in pregnancy and cancer. Expert Opin. Med. Diagn. 2008, 2:1347-1364.
34. Berger P., et al. Variants of human chorionic gonadotropin from pregnant women and tumor patients recognized by monoclonal antibodies. J. Clin. Endocrinol. Metab. 1993, 77:347-351.
35. Schwarz S., et al. The antigenic surface of human chorionic gonadotropin as mapped by murine monoclonal antibodies. Endocrinology 1986, 118:189-197.
36. Dirnhofer S., et al. The molecular basis for epitopes on the free beta-subunit of human chorionic gonadotrophin (hCG), its carboxyl-terminal peptide and the hCG beta-core fragment. J. Endocrinol. 1994, 141:153-162.
37. Jackson A.M., et al. Identification and selective destruction of shared epitopes in human chorionic gonadotropin beta subunit. J. Reprod. Immunol. 1996, 31:21-36.
38. Charrel-Dennis M., et al. The major hormone-specific discontinuous epitopes on human chorionic gonadotrophin. J. Mol. Endocrinol. 2004, 32:571-581.
39. Dirnhofer S., et al. Free alpha subunit of human chorionic gonadotrophin: molecular basis of immunologically and biologically active domains. J. Endocrinol. 1994, 140:145-154.
40. Schwarz S., et al. Number and topography of epitopes of human chorionic gonadotropin (hCG) are shared by desialylated and deglycosylated hCG. Mol. Cell. Endocrinol. 1991, 80:33-40.
41. Lottersberger C., et al. Tumor- and pregnancy-derived isoforms of human chorionic gonadotropin: biological and diagnostic relevance. Horm. Res. 2003, 59:125-134.
42. Berger P., et al. Monoclonal antibodies against the free subunits of human chorionic gonadotrophin. J. Endocrinol. 1990, 125:301-309.
43. Klonisch T., et al. Enhancement in antigen binding by a combination of synergy and antibody capture. Immunology 1996, 89:165-171.
44. Sturgeon C.M., Viljoen A. Analytical error and interference in immunoassay: minimizing risk. Ann. Clin. Biochem. 2011, 48:418-432.
45. Gronowski A.M., et al. False-negative results in point-of-care qualitative human chorionic gonadotropin (hCG) devices due to excess hCGbeta core fragment. Clin. Chem. 2009, 55:1389-1394.
46. Nerenz R.D., et al. Screening method to evaluate point-of-care human chorionic gonadotropin (hCG) devices for susceptibility to the hook effect by hCG beta core fragment: evaluation of 11 devices. Clin. Chem. 2014, 60:667-674.
47. CDRH (2000) Guidance for Over-the-Counter (OTC) Human Chorionic Gonadotropin (hCG) 510(k)s. U.S. Department Of Health and Human Services FDA, GDRH . http://www.fda.gov/MedicaIDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm092791.htm.
48. Bock, J.I. (1996) Choriogonadotropin testing: nomenclature, reference preparations, assay performance and clinical application; approved guideline. In NGGLS document, l/LA 10-A, v. 16, no 14 (Wayne, P., ed).
49. Stenman U.H., Alfthan H. Determination of human chorionic gonadotropin. Best Pract. Res. Clin. Endocrinol. Metab. 2013, 27:783-793.
50. Madersbacher S., Berger P. Antibodies and immunoassays. Methods 2000, 21:41-50.
51. Grenache D.G., et al. Falsely decreased human chorionic gonadotropin (hCG) results due to increased concentrations of the free beta subunit and the beta core fragment in quantitative hCG assays. Clin. Chem. 2010, 56:1839-1844.
52. Sturgeon C.M. External quality assessment of hormone determinations. Best Pract. Res. Clin. Endocrinol. Metab. 2013, 27:803-822.
53. Sturgeon, C.M. et al. (2014) Annual review for 2013 - pregnancy testing (urinary hCG). In UK NEQAS for Peptide Hormones, pp. 50-52, [Available on request from ukneqas@ed.ac.uk].
54. Alfthan H., et al. Specificity and detection limit of ten pregnancy tests. Scand. J. Clin. Lab. Invest. Suppl. 1993, 216:105-113.
55. Gronowski A.M., et al. Use of serum FSH to identify perimenopausal women with pituitary hCG. Clin. Chem. 2008, 54:652-656.
56. Snyder J.A., et al. Diagnostic considerations in the measurement of human chorionic gonadotropin in aging women. Clin. Chem. 2005, 51:1830-1835.
57. Terwijn M., et al. Pregnancy detection by quantitative urine hCG analysis: The need for a lower cut-off. Clin. Chim. Acta 2013, 424:174.
58. Cole L.A., Ladner D.G. Background hCG in non-pregnant individuals: need for more sensitive point-of-care and over-the-counter pregnancy tests. Clin. Biochem. 2009, 42:168-175.
59. Cate F.L., et al. Analytical and clinical validation of the Immulite 1000 hCG assay for quantitative analysis in urine. Clin. Chim. Acta 2013, 421:104-108.
60. Sturgeon C.M. Common decision limits - the need for harmonised immunoassays. Clin. Chim. Acta 2013, 432:122-126.
61. John W.G., Diabetes U.K.D.o.H.A.C.o. Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011. Diabet. Med. 2012, 29:1350-1357.
62. Krause J.M., et al. Rapid maturation of glycoprotein hormone free alpha-subunit (GPHalpha) and GPHalpha alpha homodimers. Mol. Endocrinol. 2007, 21:2551-2564.
63. Hoermann R., et al. Immunological recognition and clinical significance of nicked human chorionic gonadotropin in testicular cancer. Clin. Chem. 1994, 40:2306-2312.
64. Stenman U.H., et al. Standardization of protein immunoprocedures. Choriogonadotropin (CG). Scand. J. Clin. Lab. Invest. Suppl. 1993, 216:42-78.